{kanada_flagge}Predictmedix AI Inc (CSE: PMED; OTCQB: PMEDF; FRA:3QP) has secured a renowned Indian supplier for the mass production of its AI-assisted Safe Entry Stations. The collaboration is expected to provide Predictmedix AI with increased production capacity, faster turnaround times and cost efficiencies. According to Predictmedix AI, the unnamed partner has extensive production capacity and can easily scale production. By leveraging the expertise of its new supplier, Predictmedix AI aims to make Safe Entry more accessible to companies of all sizes.
Summary: Predictmedix AI recently added the acronym “AI” to its name to be more easily recognized in the market as a player in the emerging artificial intelligence business. The capabilities of the technology are evolving rapidly, opening up ever new diagnostic fields for Predictmedix AI. Just as important, however, is the extensive data validation the company is getting in East Asia through free of charge testing with renowned medical institutions. Such tests usually cost millions of dollars. One should therefore value the company on at least two criteria: future sales growth in the mass market in India or Indonesia is one component. The other is the value of the technology in conjunction with the ever-expanding trove of data. Either way, artificial intelligence will play an increasingly important role in medical diagnostics in the future – not least because there is a lack of personnel for individualized diagnosis.
{kanada_flagge}Predictmedix AI Inc (CSE: PMED; OTCQB: PMEDF; FRA:3QP) has secured a renowned Indian supplier for the mass production of its AI-assisted Safe Entry Stations. The collaboration is expected to provide Predictmedix AI with increased production capacity, faster turnaround times and cost efficiencies. According to Predictmedix AI, the unnamed partner has extensive production capacity and can easily scale production. By leveraging the expertise of its new supplier, Predictmedix AI aims to make Safe Entry more accessible to companies of all sizes.
Dr. Rahul Kushwah, COO of Predictmedix commented, “We are very excited to be working with our valued Indian supplier to accelerate the mass production and deployment of Safe Entry. We are working with a supplier that is capable of providing thousands of units in a very short period of time. The company’s state-of-the-art facilities and manufacturing expertise will play a critical role in our efforts to improve public safety worldwide. This collaboration will allow us to reach a wider audience and make a significant contribution to creating safer environments.”
Safe Entry uses advanced AI algorithms and multispectral imaging to non-invasively detect various biological and psychological parameters that provide information about a person’s current health status, contributing to the health, safety and security of companies or organizations. Typical places of use are at the workplace, in schools, in healthcare facilities.
Predictmedix AI provides AI-powered solutions for rapid health screenings and remote patient care worldwide. The company’s Safe Entry Stations use multispectral cameras to analyze physiological data patterns and diagnose a variety of health issues, including infectious diseases such as COVID-19, impairment from drugs or alcohol, fatigue, or various mental health conditions. The remote patient care platform developed by Predictmedi AI gives medical professionals a set of AI-powered tools to improve patient health.
Last week the company unveiled contactless integrative AI solutions for health care which is poised to revolutionize the industry in India. A report on the National Strategy for Artificial Intelligence by the NITI Aayog showed that shortage of qualified health care professionals and non-uniform accessibility to health care across the country prevails. India has only 64 doctors available per 100,000 people compared to the global average of 150. This significant disparity highlights the urgent need for innovative solutions to bridge the health care gap and improve health care outcomes for the Indian population.
Summary: Predictmedix AI recently added the acronym “AI” to its name to be more easily recognized in the market as a player in the emerging artificial intelligence business. The capabilities of the technology are evolving rapidly, opening up ever new diagnostic fields for Predictmedix AI. Just as important, however, is the extensive data validation the company is getting in East Asia through free of charge testing with renowned medical institutions. Such tests usually cost millions of dollars. One should therefore value the company on at least two criteria: future sales growth in the mass market in India or Indonesia is one component. The other is the value of the technology in conjunction with the ever-expanding trove of data. Either way, artificial intelligence will play an increasingly important role in medical diagnostics in the future – not least because there is a lack of personnel for individualized diagnosis.
Disclaimer: GOLDINVEST Consulting GmbH publishes comments, analyses and news on https://goldinvest.de. These contents are exclusively for the information of the readers and do not represent a call to action, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. Furthermore, they are in no way a substitute for individual expert investment advice and do not constitute an offer to sell the discussed stock(s) or a solicitation to buy or sell securities. It is expressly not a financial analysis, but a promotional/journalistic text. Readers who make investment decisions or execute transactions on the basis of the information provided here do so exclusively at their own risk. There is no contractual relationship between GOLDINVEST Consulting GmbH and its readers or the users of its offers, because our information refers only to the company, but not to the investment decision of the reader.
The acquisition of securities is associated with high risks, which can lead to a total loss of the invested capital. The information published by GOLDINVEST Consulting GmbH and its authors is based on careful research. Nevertheless, any liability for financial losses or the content guarantee for topicality, correctness, adequacy and completeness of the articles offered here is expressly excluded. Please also note our terms of use.
Pursuant to §34b WpHG and §48f Abs. 5 BörseG (Austria) we point out that GOLDINVEST Consulting GmbH and/or partners, principals or employees of GOLDINVEST Consulting GmbH hold shares in Predictmedix and therefore a conflict of interest exists. GOLDINVEST Consulting GmbH also reserves the right to buy or sell shares of the company at any time. Furthermore, GOLDINVEST Consulting GmbH is remunerated by Predictmedix for reporting on the company. This is another clear conflict of interest.
